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for critical limb ischemia
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Darryl McMillan, CCP,e,f,g Seiji Itoh, MD,e Greg Roger, MD,d and Rodney J. Lane, MD,a,b,c,e,f,g
Macquarie Park, St. Leonards, and Killara, New South Wales, Australia
Objective: This article reports the early results in humans of hypertensive extracorporeal limb perfusion (HELP)
technology in the prevention of major limb amputation due to ischemia. The short-term aim was to dilate pre-existing
collateral channels, and the long-term aim was to stimulate remodeling and new collateral development by increasing
endothelial shear stress and wall tension.
Methods: This study evaluated 20 patients with critical limb ischemia who were treated with HELP. These patients had no
other option but major amputation, as determined by at least two vascular surgeons. The arterial circulation to the
ischemic limb was isolated from the systemic circulation by the use of an endoluminal balloon catheter in seven patients
and by an implantable, inﬂatable, occlusive cuff in 13. The limbs were hyperperfused through the peripheral access system
with an extracorporeal pump, producing a minimally pulsatile waveform at 200% to 300% of the mean arterial pressure.
This was performed repeatedly in sessions of 24 to 36 hours, up to a maximum of 74 hours. The primary end point
was avoidance of major amputation. The secondary end points were the clinical improvements in rest pain, ulcer healing,
and claudication distance. Patients were analyzed and reviewed using infrared thermography and ultrasound imaging
parameters of the limb.
Results:Given adequate arterial access, 39 of 40 connections developed ﬂows four to eight times those supplied to the limb
by the normal cardiac output. A progressive decrease was noted in peripheral resistance. All patients developed a pain-free,
warm foot or hand while on the pump in the short-term. In the longer term at a mean of 22 months (range, 12-54
months), eight of 20 patients (40%) had avoided major amputation and four more had a delay in amputation of an
average of 4 months. The ankle-brachial index changed from 0.04 6 0.07 (range, 0.00-0.94) to 0.63 6 0.39 (t-test,
P < .05). Bleeding, infection, premature cessation of the treatment, and poor patient selection resulted in the failures.
There were two short-term unrelated deaths that occurred at 1 and 3 months follow-up.
Conclusions: The collateral circulation of ischemic limbs canbe augmented and regulatedby a connection to an extracorporeal
centrifugal pump, with isolation from the systemic circulation provided by balloons and with an access system providing
repeatable pump connections. Major amputation may be avoided in selected cases. (J Vasc Surg 2013;58:1244-53.)Despite advances in endovascular and open surgical care system, particularly with repeat vascular procedures,
techniques for critical limb ischemia (CLI), lower limb
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4demand a greater scientiﬁc effort to achieve a simpler and
longer lasting solution.1 Collateral circulation can be
augmented and regulated by connection to an extracorpo-
real pump at suprasystolic pressures with isolation of the
ischemic segment from the systemic circulation by the
use of occlusive balloons.2 This has been achieved by
the design of a speciﬁc arterial access system to withstand
the suprasystolic pressures and high ﬂows similar to those
obtained in physiologic peak exercise. In the longer-term,
high levels of ﬂuid shear stress (FSS) have been shown to
be the moulding force in arteriogenesis.3 The molecular
factors mediating gene upregulation of vascular prolifera-
tion have been associated with changes of blood ﬂow at
the endothelial interface, particularly via monocyte chemo-
attractant protein 1.4-7 Inherent in the concept is that new
collaterals may be less susceptible to atheromatous degen-
eration than the native vessels.
The aims of this article are to:
1. Demonstrate the structure and function of the periph-
eral access system (PAS) in humans;
2. Report the results in 20 patients for whom major limb
amputation was the only option available for their CLI;
3. Report the obstacles encountered in the developmental
phase of the technique; and
Fig 1. Schematic shows two peripheral access systems (PASs) with isolation from the systemic circulation via an
inﬂatable extravascular balloon. Device 1 is the inﬂow from the heart to the pump. Device 2 takes blood from the pump
to the isolated limb at high pressures and ﬂows.
Fig 2. The inﬂatable balloon is placed circumferentially around
the arterial inﬂow to isolate the ischemic limb. The diameter is
ﬁxed via sutures through the strap. The tube is passed externally
for manual inﬂation and deﬂation as required.
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maximize the safety and efﬁcacy of the technique.
METHODS
Patients. A cohort of 20 patients were evaluated
for this report. Procedures in ﬁve patients were approved
by the Northern Sydney and Central Coast Human
Research Ethics Committee (NSCC HREC) New South
Wales, Australia (Protocol 0501-021M). Ten patients
were treated under the Special Access Scheme by the
Therapeutic Goods Administration Australia, following
a similar clinical protocol. Five more patients were
part of a registered clinical trial (ACTRN1261000011
8000) approved by the NSCC HREC (Protocol 0911
-306M).
All 20 patients were destined for major amputation.
Multiple vascular procedures (mean, 4.5) had failed in 19
of the 20 patients. Six patients had diabetes, and one had
essential thrombocytosis.
The inclusion criteria were:
1. All patients had end-stage CLI with any or all of rest
pain, tissue loss, or gangrene;
2. All standard operative and endovascular measures had
been exhausted;
3. All had been offered amputation by at least one other
vascular surgeon;
4. All had high-quality angiography at a small-vessel level
with all three calf vessels occluded and no reconstitu-
tion distally;
5. There was clinical and angiographic evidence of good
inﬂow.The exclusion criteria were:
1. General cardiac, respiratory, and renal disease of
signiﬁcance;
2. Mental instability;
Fig 3. A polytetraﬂuoroethylene adventitia “skirt” is placed
around the primary anastomosis to minimize bleeding. This is
ﬁxed to the adventitia by a continuous PROLENE suture (Ethi-
con, Somerville, NJ) after appropriate fashioning.
Fig 4. Two ﬂexible access systems in situ in the right common
femoral artery with exit cutaneous foramina. The extravascular
balloon cuff is not visible. The metal caps lock the internal plunger
in position to avoid patient tampering. Device 1 is the inﬂow from
the heart to the pump. Device 2 takes blood from the pump to the
isolated limb at high pressures and ﬂows.
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4. Vessels not capable of access and anastomosis;
5. Signiﬁcant myonecrosis.
Materials. All PASs were supplied by AllVascular Pty
Ltd (St. Leonards, New South Wales, Australia). The initial
approach was to apply a single arterial access system using
an endoluminal occlusion and saphenous system.2 The
preferred approach is shown in Fig 1, with inﬂowandoutﬂow
tubeswith an extravascular inﬂatable cuff (Fig 2) between the
two access systems. This setup facilitated for high pressure
and large volume ﬂows >500 mL/min, particularly where
the superﬁcial femoral artery was occluded.
The pumping system used was a Maquet Jostra ROTA-
FLOW centrifugal pump system (Hirrlingen, Germany). The
thermographic imaging system used was the NECTH7800N
Thermotracer (Tokyo, Japan). The thermographic assessment
methodology has been described previously.2
OPERATIVE METHOD
Implantation. A standard surgical approach to the
arteries of the groin or axilla was used. A standardend-to-side anastomosis was performed, and a further
polytetraﬂuoroethylene “skirt” was sutured around the
primary anastomosis to minimize bleeding (Fig 3). These
sutures were from the skirt to the adventitia of the host
vessels and were circumferential around the primary anas-
tomosis. The input and output PASs have their own indi-
vidual cutaneous exit (Fig 4) with a hairy Dacron (DuPont,
Wilmington, Del) cuff between each PAS and the subcu-
taneous tissue (Fig 1). The anastomoses were situated at
least 1.5 cm apart to allow an inﬂatable occluder cuff to be
implanted in between the two PASs. The inﬂatable
occluder cuff has its own individual subcutaneous exit for
its inﬂation port. The wounds were closed. Extracorporeal
pumping was performed in the intensive care unit, and the
patients were transferred to the standard ward accommo-
dation after disconnection.
Explantation. Explantation occurred 5 to 18 days
after implantation. The access wounds were reopened.
After the vessels were controlled, the PASs and occlusive
devices were removed, and no foreign bodies were left in
situ. The arteriotomies were directly closed or patched
with autogenous material. The wounds were irrigated
with antibiotic solution and closed with drainage. Intrave-
nous antibiotics were given according to the swab results
from the ischemic ulcers during implantation, pump
sessions, and explantation. Oral equivalents were given
between these times.
Hematologic assessments. Serial full blood counts,
biochemistry, and plasma free hemoglobin, D-dimer, and
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pumping sessions, careful monitoring of the heparin anti-
coagulation was afforded by using an hourly measurement
of the activated clotting time, which was kept between
160 and 180 seconds. Antiplatelet agents (clopidogrel)
were used routinely to inhibit clot formation. Between
pumping sessions, the patients had a standard anticoagula-
tion with heparin as a continuous infusion, with a partial
thromboplastin time of twice controls, or subcutaneous
enoxaparin (1.25 mg/kg) if there was no intravenous
access.
Pumping method. Connection can be at the time of
the original operation or delayed to allow better hemo-
stasis at the anastomosis. After pump connection, the
infusion pressures are established at 300% of the mean
arterial pressure (MAP; maximum of 300 mm Hg due
to device limits). The MAP was monitored with an arterial
catheter in the patient’s lower arm. Pump pressure,
suction pressure blood ﬂows, and MAP were recorded
every 30 minutes.
Baseline and subsequent progress evaluation. When
the pump is connected and ﬂow established, the pump revo-
lutions are decreased so that the measured pressure through
the system equals the MAP. The measured ﬂow is the base-
line. The initial resistance of the system and the limb can be
calculated. The inﬂow pressures were increased to produce
a clinically warm, painless limb. As time progresses, the ﬂows
increase and the pressures required decrease.When the revo-
lutions are decreased so that the pressures are once again
close to the MAP, then the resistance that the heart will
face without the pump can be assessed.
When the ﬂows are four to eight times the baseline
ﬂow, the pump can be disconnected. The indications for
reconnection are recurrence of ischemic symptoms or
a decrease in the thermographic and or ultrasound baseline
parameters with poor monophasic ﬂow. When the pump is
reconnected, a low initial peripheral resistance indicates
a good long-term prognosis and early disconnection.
Concerns about infection in recent wounds with trans-
cutaneous foreign material connected to arteries are factors
that promote early removal of the devices.
RESULTS
The pumping hours, mean ﬂow rates, peak ﬂows
(mL/min), mean perfusion pressures, and peak pressures
(mm Hg) are summarized in Table I. Peak pressures of
up to 366 mm Hg (mean 6 standard deviation: 240.6 6
53.77 mm Hg) creating ﬂows up to 1400 mL/min
(694 6 265.6 mL/min) were delivered safely to 19 of
20 ischemic limbs. One of the 20 limbs could not be
perfused due to an unrecognized iliac dissection that pro-
hibited adequate inﬂow. The overall mean perfusion pres-
sure was 191 6 39.54 mm Hg delivering 523 6 195.4
mL/min through collaterals. These values were four to
eight times the ﬂow provided to the limb by the normal
cardiac output. Patient outcomes at a mean of 12 months
(range, 1-29 months) are summarized in Table II. Whilebeing treated with the pump, 18 of 19 patients (94.74%)
were noted to have an essentially pain-free, well-perfused,
warm extremity. The single exception was the patient
with underestimated myonecrosis at the onset.
Limbs were intact in eight of the 19 who had adequate
pump connection. Four patients had a mean delay of 4
months in the below-knee amputation, despite signiﬁcant
improvement in their initial post-treatment clinical picture
(Table II). Seven of the eight patients had healed ulcers at
the latest follow-up, with improvement in the single
residual, who had a neurogenic component. Creatinine
phosphokinase was elevated in two patients, one with
pre-existing myonecrosis and the other with inadvertent
balloon deﬂation due to a transient increase in distal
ischemia. There was no evidence of hemolysis, with normal
plasma free hemoglobin, or platelet activation due to
pump-induced negative pressures. There were two long-
term deaths >30 days. Complications are summarized in
Table III.
Pain assessment documented in the visual analog score
changed from 9.0 6 0.1 to 1.1 6 0.3 (t-test, P < .05) at
the latest follow-up. The ankle-brachial index (ABI)
measurements changed from 0.04 6 0.07 (range, 0.0-
0.94) to 0.63 6 0.39 (t-test, P < .05) at the latest
follow-up visit. Claudication was improved, but this vari-
able was confounded by other factors such as coexisting
osteoarthritis in the knee or contralateral peripheral
vascular disease (Table II). The thermographic imaging
system showed noticeable differences between the treated
limb and the untreated limbs in 19 of the 20 patients while
connected to the pump and in 11 patients at the last
follow-up visit.
A typical pumping sequence for 24 hours is shown in
Fig 5. There is progressive improvement in ﬂow, with
a decreasing pressure required to produce that ﬂow.
Fig 6 shows the relationship between pressure and ﬂow
at different times and at various pump speeds. The gradient
is the peripheral resistance. When the limbs are initially
hyperperfused, the resistance is high. If the pump speed
is varied so that the inﬂow pressure equates to the MAP,
the ﬂow through the limb is almost undetectable. Because
the pressure-ﬂow relationship is a straight line, retrograde
projection of the resistance gives an estimate of the resis-
tance of the pump itself and its associated tubing at the
MAP. In this example, the initial ﬂow rates are <200
mL/min, but the ﬂow rate at the MAP is w450 mL/
min after 24 hours of pumping. This has been designated
as short-term pressure-induced collateral dilatation
(PICD). The temporary PICD, along with the pressure
gradient, results in an increased ﬂow rated during the
pumping session and thus greater FSS at the arterial walls
to stimulate arteriogenesis and collateral growth. When
the pump is initially reconnected after 3 or 4 rest days off
the pump, the resistance resumes a similar, but improved,
value from the base value. Thereafter, there is a gradual
and long-term affect of the temporary PICD with each
individual connection.
Table I. Pump ﬂows and pressures
Patient Age/sex Pumping sessions
Pumping hours
S1a S2 S3 Total
Protocol 0501-021M MB551b 52/M 2 19 28 . 47.0
RB567 57/M 1 59.5 . . 59.5
FW853 85/M 2 6.5 18 . 24.5
GH237b 61/M 2 33.5 24 . 57.5
MM565 86/F 2 24 11.5 . 35.5
Special Access Scheme,
Therapeutic Goods Administration
EC968c 86/M 2 27 29 . 56.0
MB840 86/F 2 28.5 24.25 . 52.8
IM879 79/M 1 17.5 . . 17.5
JV313b 65/M 2 26 36 . 62.0
MI731 76/M 2 26.5 30 . 56.5
GC319 72/M 2 19.75 22.75 . 42.5
KH592b 73/M 2 24 24.75 . 48.8
ED238b 62/M 2 26 25.42 . 51.4
BB002 67/M 2 25 32.5 . 57.5
SL314 67/F 3 23 23.5 24.33 70.8
LP301 68/M 3 18.5 18.5 24 61.0
Protocol 0911-306M GB304 79/M 1 20 . . 20.0
KW307 76/M 1 23.5 . . 23.5
CM305 70/F 3 25 24 27.5 76.5
MP306 82/F 3 24 26 21 71.0
F, Female; M, male.
aSn, nth pumping session.
bSuperﬁcial femoral artery open.
cUpper limb patient.
Table II. Clinical outcome of 20 patients
Patient 1 week Latest follow-up Outcome at latest follow-up
MB551a Immediate pain relief 29 months Forefoot amputation; leg viable, healed ulcer
RB567 Leg amputated 1week AKA
FW853 No pain 3 days BKA 3 months after treatment
GH237a Pain negligible 15 months Leg viable; ulcers healed
EC968 b Pain-free ﬁngers 13 months Hand saved
MB840 Pain “low to medium;” gangrenous
1st toe amputated
4 months Post-treatment infection; AKA
MM565 Minimized pain 1 month Died of exacerbation of pre-treatment
respiratory failure
IM879 No access, pumping abandoned 12 months BKA
JV313a Pain-free leg 18 months Leg viable
MI731 Pain 4/10; leg appears warmer 3 months Ulcer healed; forefoot amputated
Amputation site viable, leg viable
GC319 Ulcer still sore; foot feels warmer than before 5 months BKA at 5 months
KH592a No pain when lying down; pain 3/10 in toe
upon contact, 0/10 in leg
5 months Delayed BKA
ED238a Pain in ulcer negligible 3 months Ulcer improved; some pain
BB002 Leg pain 2/10 6 weeks BKA 6 weeks post-treatment
SL314 Pain absent 5 weeks Infection, AKA at 5 weeks
LP301 Leg amputated; BKA 3 months BKA
GB304 Leg viable; pain 1/10 6 months Limb viable
KW307 Leg viable; pain 1/10 6 months Limb viable
CM305 Leg viable; pain 8/10 3 months BKA
MP306 Leg viable; pain 4/10 3 months Died of cardiac and renal failure
ABI, Ankle-brachial index; AKA, above-knee amputation; BKA, below-knee amputation;NA, not applicable; PPG, photoplethysmograph; VAS, visual analog
scale.
aSuperﬁcial artery open.
bUpper limb patient.
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Mean ﬂow per treatment,
mL/min Mean pressure, mm Hg Peak ﬂows, mL/min Peak pressure, mm Hg
S1 S2 S3 S1 S2 S3 S1 S2 S3 S1 S2 S3
349 355 . 234 121 . 430 450 . 366 150 .
294 . . 196 . . 520 . . 279 . .
276 193 . 179 303 . 294 300 . 220 350 .
308 788 . 285 184 . 400 1006 . 330 233 .
894 474 . 181 200 . 1100 700 . 228 245 .
498 372 . 154 169 . 650 410 . 167 190 .
437 444 . 211 217 . 670 560 . 263 296 .
112 . . 130 . . 240 . . 145 . .
567 686 . 175 171 . 670 860 . 267 212 .
615 601 . 187 206 . 760 880 . 306 243 .
385 393 . 244 290 . 490 470 . 302 313 .
468 448 . 187 175 . 740 670 . 262 196 .
558 518 . 166 147 . 730 770 . 290 222 .
711 756 . 148 152 . 870 1000 . 179 190 .
486 656 634 205 204 188 690 770 770 221 230 207
808 744 858 204 198 206 1110 1020 1060 237 276 247
695 . . 169 . . 920 . . 196 . .
366 . . 140 . . 470 . . 170 . .
724 663 773 207 196 194 900 760 1400 248 257 299
326 433 258 149 187 181 450 510 290 180 204 209
Table I. Continued.
Post-op walking distance, mm
ABI (PPG)
Ulceration VAS pain scoreBefore After
$500 (0.2) (0.36) Healed 0/10
NA NA NA NA NA
$100 0.1 0.3 NA NA
$100 0 (0.21) Healed 1/10
Unrestricted 0 1 Healed 0/10
$100 0 NA NA NA
NA 0.1 0.35 NA NA
$100 0 NA NA NA
$500 0.2 1 Healed 0/10
500 0 0.74 Healed 0/10
$100 0 0.27 Ulcer neurogenic NA
Contralateral BKA 0 0.3 Healed 1/10
$100 0 1 (0.43) Yes 3/10
50 0 0.47 Toe 2/10
50 0 0.4 NA 3/10
NA 0 NA NA NA
$500 0 0.62 Healed 0/10
50 0 1.47 2 healing 0/10
NA NA NA NA NA
NA 0.94 (calciﬁcation) NA NA NA
Table II. Continued.
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Table III. Complications: Device and procedural modiﬁcations
Complication Incidence Etiology Effect Device/procedure change
Hemorrhage 3 High infusion pressure Blood transfusion required Double “skirt” anastomosis
Anticoagulation Delay in pumping
Repeat operation site Suction drainage
Multiple exit cannulas External compression
Infection 4 Gangrenous ulcers in feet Amputation at a higher level
(n ¼ 1)
Dacron isolation rings on PAS
Infected lymphatic Transient (n ¼ 2) bacteremia Early removal of device
Repeat groin procedures No residual foreign material
Longer subcutaneous tunnel
Fistula 1 Inadvertent balloon deﬂation Transient superﬁcial skin
ulceration (groin)
Routine balloon checks especially
high ﬂow with low resistance on
monitors
Embolization 1 Long ﬂow times Transient muscle pain Use high-ﬂow double PAS systems
Long pump lines Transient CPK elevation Limit pump time to 24 hours
Poor anticoagulation control Delay in ulcer healing
CPK, Creatine phosphokinase; PAS, peripheral access system.
Fig 5. A 24-hour sequence with pressure and ﬂow variation plotted against time. As time progresses, there is a gradual
increase in ﬂow with an associated decrease in the required pump pressure. This relationship reﬂects a decrease in
peripheral resistance.
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Given adequate inﬂow, the 40 connections to the
pump allowed regulation, augmentation, and variation of
the collateral circulation as required clinically in the
short-term. The gradual reduction in peripheral resistance
during a 24-hour period is shown in Fig 5. The changes
are reﬂected in the clinical picture, with resolution of rest
pain and the rapid development of a warm, pink limb.
Thermography (Fig 7) is a simple noninvasive way tocompare the preoperative superﬁcial ﬂow using the other
limb as a control. Similarly, this imaging mode can be
used to monitor postperfusion progress. The thermog-
raphy was found to be helpful in deciding whether to
reconnect the pump. The groin areas were scanned but
uniformly showed increased temperature that did not
correlate with the clinical situation.
The variation of pump speed allows control of the
inﬂow pressure. Higher ﬂow rates indicate a good PICD,
Fig 6. Graph shows pressure vs ﬂow at different times. Initial ﬂow rates are compared with those 12 hours later, after
a rest period and after pump reconnection, and then again after 24 hours. Peripheral resistance improved after different
pumping sessions.
Fig 7. Monitoring thermogram is used to indicate the need for pump reconnection. This system is helpful for long-
term follow-up. These images correspond to the clinical presentation. After receiving hyperperfusion, thermographic
improvement is maintained.
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pump is reconnected, the degree of return of collateral
smooth muscle tone is reﬂected in the initial peripheral
resistance. It is interesting that the pressure-ﬂow rategradient reduces slightly at different pump speeds
(Fig 6). These changes suggest that the increased pressure
induces dilatation of the vascular smooth muscle, which
leads to a drop in the peripheral resistance, similar to that
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1252 Khin et al November 2013induced by exercise.2 After pump disconnection, there is
recovery of smooth muscle tone. At the vascular endothe-
lial level while on the pump, there is an enormous increase
in blood ﬂow velocity. Because velocity and FSS are inti-
mately related and linked to the gradual upregulation of
genes, there is an expectation of an increase in the forma-
tion of collaterals.4-7
The pump. The centrifugal pump was the pump of
choice primarily due to its added safety measures. In an
event of a blockage or obstruction in the circuit, a centrif-
ugal pump would not continuously increase the pressure,
which could lead to rupture of the PAS or the vessel(s),
or both. In addition, it allowed for a heparinized circuit,
was portable, and was easily connected to standard tubing.
It also has automated alarm systems and a digitized reading
of suction pressures, ﬂows, and inﬂow pressures. Finally, it
has been safely used for extended periods (days) for extra-
corporeal membrane oxygenation (ECMO) for cardiac
patients, with minimal hemolysis. There was no signiﬁcant
cooling of the patient, as measured by standard tempera-
ture readings.
The evolution of the PAS. Repeated surgical groin
dissections and anastomoses with expanded polytetra-
ﬂuoroethylene grafts immediately subjected to high pres-
sures, high ﬂows, and aggressive anticoagulation create
a strong predisposition for bleeding. The double skirt anas-
tomosis was thus designed to address this issue. Since this
concept has been instituted, bleeding at this site has been
minimal. The development of separate input and output
access systems allows for greater inlet and outlet diameters,
thus eliminating the risk of hemolysis and platelet activa-
tion when using small catheters with a high negative pres-
sure. This type of conﬁguration also allows for more than
one vascular bed to be isolated and hyperperfused, for
example, a superﬁcial femoral and profunda artery
together, or by using another occlusive balloon, the pro-
funda alone.
The use of an external inﬂatable occluder cuff also
decreases the chance of thrombus compared with an endo-
vascular occlusive balloon because no foreign body is in
direct contact with the blood ﬂow. No thromboembolic
complications have been associated with external balloon
occlusion. The disadvantage of having an external inﬂatable
occluder cuff is the need for an additional small exit
foramen, which, although only 2 mm, is nevertheless pre-
disposed to skin bleeding at very high infusion pressures.
Because 19 of the 20 limbs had tissue loss or gangrene,
the patients had a high infection potential due to coloniza-
tion of their ulceration and potentially infected lymphatics.
These patients often had multiple groin procedures, which
also predisposes to an infective risk. In addition to appro-
priate antibiotics, technical changes have been instituted
to minimize the infective complications. The length of
the PAS and the length of the subcutaneous tunnel were
increased with the addition of multiple circumferential
Dacron infection shields. Other measures include a separate
exit wound for the access system and the use of autogenous
materials for arterial patches to close arteriotomies whenthe devices are removed. Often, the endarterectomized
superﬁcial femoral artery or residual autogenous grafts
were used.
Repeatability. The long-term development of collateral
circulation depends on the FSS. The optimal time for devel-
opment of gene upregulation is ostensibly 3 weeks.4-6 In 10
patients, despite very successful pumping procedures, the
result was limb loss with the gradual redevelopment of rest
pain, and the ulcer failed to heal completely in one patient.
External arteriovenous shunts have been used for long-
term hemodialysis for periods of many months and years
without insurmountable adverse events.8-10 The HELP
technology is an advancement of this but still requires
a better understanding of collateral development to tailor
ﬂow requirements in the short-term and long-term. Further
investigations could include analysis of the overall duration
of the treatment, individual treatment durations, frequency
of cycles, pressure proﬁles, and optimal adjuvant therapy
(ie, physiotherapy or drug therapy, or both). There is an
urgent need for measurable biochemical markers to reliably
predict the development of adequate collateralization,
thereby deﬁning treatment repeatability. The ABI increase
in these patients reﬂects this inadequacy. However, because
many of these vessels were heavily calciﬁed, no ﬂow could be
detected on presentation, then after hyperperfusion, the
increased ﬂow might be artiﬁcially elevated in the ABI.
Future developments. Optimization of the access
system is ongoing. Pump specialization and size minimiza-
tion may allow greater portability. The concept of regional
hyperperfusion can be used for other ischemic organs
and has already been shown in the carotid circulation.2
Furthermore, the continuous perfusion dramatically
increases the total ﬂow through a vessel without the peak
perfusion pressure having to be increased, largely due to
increased diastolic ﬂow. Theoretically, this may minimize
the risk of intracerebral hemorrhage while increasing
collateral ﬂow for occlusive cerebral disease. Further basic
research is required to demonstrate applicability in stroke
patients and other ischemic vascular beds. In retrospect,
shorter multiple hyperperfusion episodes (perhaps 8 hours,
similar to hemodialysis) and accessing the blood ﬂow from
a remote source (axilla or either leg) might improve
collateral distribution and growth.
CONCLUSIONS
The collateral circulation can be augmented and regu-
lated by connection to an extracorporeal cardiac pump.
Isolation from the systemic circulation provided by
balloons and the PAS allows intermittent pump connec-
tion. Major amputation may be avoided in selected patients
when all other measures have failed. Further research and
deﬁnition of confounding variables are being deﬁned in
a prospective controlled clinical trial.
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